News and Updates | Page 2 | Richard T. Silver MD Myeloproliferative Neoplasms Center

9th International Patient Symposium on Myeloproliferative Neoplasms

November 16, 2017

On November 1st, Weill Cornell Medicine and the Cancer Research & Treatment (CR&T) Fund hosted a full-day educational event for over 200 patients and their families to learn about the latest developments in the research and treatment of myeloproliferative neoplasms (MPNs).

Weill Cornell Medicine Team Creates Self-Renewing Hematopoietic Stem Cells for Transplantation

October 3, 2017

Hematopoietic stem cells (HSCs) are long-lasting cells that mature into all types of blood cells: white blood cells, red blood cells and platelets. Almost a trillion new blood cells must be replaced each day to replace normal loss of old blood cells. “Bone Marrow Transplant” is a procedure currently used by clinicians to transplant HSCs and cure a wide range of blood diseases. But not all patients have a suitable donor for a HSC transplant. For the first-time ever, Dr.

The MPN Interferon Initiative

September 15, 2017

Dr. Joseph Scandura selected as one of four investigators for a new, multi-institution project launching in 2018: The MPN Interferon Initiative. This research project aims to evaluate how targeting the interferon pathway can be used to treat MPN patients and why this is effectively in only a subset of patients.

Visiting Professor Dr. Richard Stone Teaches Hematology & Oncology Fellows

August 11, 2017

Dr. Richard Stone, Professor of Medicine at Harvard University Medical College visits Weill Cornell Medical College. Dr. Stone is pictured here teaching Hematology and Medical Oncology Fellows.

Dr. Ellen Ritchie Reflects on Research Underway in Myeloproliferative Neoplasms

June 21, 2017

Dr. Ritchie speaks at the OncLive Summit.

Researchers are examining a variety of therapeutic regimens for patients with myeloproliferative neoplasms (MPNs), as well as working to obtain a deeper understanding of the biology of these conditions. This includes investigating combining new biologic agents with FDA-approved therapies in order to improve response rates and quality of life (QOL). Dr.

CR&T Visits Silver MPN Center Lab

June 8, 2017

The Cancer Research and Treatment Fund (CR&T) Board Members visit the research laboratory of Dr. Joseph Scandura, Scientific Director of the Silver MPN Center.

2016 MPN Congress

November 3, 2016

The 2016 MPN Congress, “Myeloproliferative Neoplasms for the Practitioner: Diagnosis, Management and New Clinical Developments” was held on November 3-5, 2016 in Brooklyn, New York.

Dr. Joseph Scandura Appointed Silver MPN Center Scientific Director

October 19, 2015

Joseph Scandura, M.D., Ph.D., has been named Scientific Director of the Richard T. Silver, M.D. Myeloproliferative Neoplasms Center at Weill Cornell Medicine. In this newly created position, Dr. Scandura will oversee clinical and basic research targeting myeloproliferative neoplasms (MPNs), a group of diseases causing excessive production of certain blood cells by the bone marrow.

Silver MPN Center Ribbon Cutting Ceremony and Dedication

February 28, 2014

The Richard T. Silver MD Myeloproliterative Neoplasm Center at Weill Cornell Medicine was established in 2013 with a $3.7 million gift from the Cancer Research & Treatment Fund (CR&T) in honor of Dr. Richard T.

Dr. Andrew Schafer Appointed Director of the Silver MPN Center

October 22, 2013

Dr. Andrew Schafer has been appointed director of the Richard T. Silver, M.D. Myeloproliferative Neoplasms (MPN) Center at Weill Cornell Medicine.

MPNs encompass four main blood diseases: chronic myeloid leukemia or CML, in which bone marrow manufactures too many white blood cells; polycythemia vera, characterized by too many red blood cells; essential thrombocythemia, defined by excess platelets; and primary myelofibrosis, scarring of the bone marrow.